Advancing Respiratory Medicine

The MediPines AGM100® provides fast, accurate, and non-invasive assessments of pulmonary gas exchange to improve diagnostic decisions.
Learn More

Global Respiratory Disease

We are the market leader in non-invasive, rapid assessment of pulmonary gas exchange.

COVID-19: 676 million people
Pneumonia: 450 million people annually
Asthma: 350 million people
COPD: 200 million people

Improve Patient Outcomes

Non-Invasive
Achieve over 90% patient compliance with our breathing circuit.
High Precision
PaO2 accuracy of over 95% compared to traditional ABG.
Single Operator
No labs, blood draw or complex set up. No calibration required.
Multi-parameter
In less than 2 minutes, we provide 12 cardiopulmonary diagnostic parameters

Use Cases

Improve diagnostic decisions across the continuum of care. From the emergency room to out-patient clinics, our device has helped patients receive faster, more accurate diagnosis.
Learn More

How the AGM100 Works

Gas exchange measurement in under 90 seconds

See how it works

Award winning medical device, trusted by doctors and patients

AGM100 selected by WHO

Medical Innovation

who-cover-web

“Innovative technologies are accelerating access to healthcare everywhere, we must ensure that they (innovative technologies) are readily available in all health facilities, fairly priced and quality-assured”

- WH0 Assistant Director General

 

Medical Design Award

AGM100 receives special designationmdea design award

 MediPines AGM100® device has been awarded the prestigious MDEA Award for Testing and Diagnostic Products in the 2021 Medical Design Excellence Awards

Seattle-Childrens
Rush-logo
freemanlogo
advent-health-logo
stevensonmemoriallogo

News and Updates

Our Latest Publications

Read about the latest publications and learn the science behind the AGM100.